Rib-X Pharmaceuticals, Ligand Pharmaceuticals' partner, has commenced Phase 3 trial of a Captisol-enabled intravenous (IV) formulation of delafloxacin to treat acute bacterial skin and skin structure infections (ABSSSI). According to the ...
Tags: Rib-X, Pharmaceuticals